Insulet (NASDAQ:PODD) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Insulet from “hold” to “buy.” Analyst views remain mixed overall: MarketBeat reports 12 Buy, 12 Hold and one Sell rating, with an average price target of $185.38.
• Insulet reported quarterly EPS of $1.99, beating the $1.59 consensus, and revenue of $842 million, above estimates and up 19.2% year over year.
• Shares were down 6.2% and opened at $146.51; analysts cited competition and a more cautious 2027 outlook as risks despite recent target increases.

Insulet (NASDAQ:PODD - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

PODD has been the topic of several other research reports. Oppenheimer lowered Insulet from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $200.00 price target on shares of Insulet in a research note on Wednesday. TD Cowen reaffirmed a "hold" rating on shares of Insulet in a research report on Wednesday. UBS Group upped their price objective on Insulet from $150.00 to $171.00 and gave the stock a "neutral" rating in a report on Thursday. Finally, Sanford C. Bernstein boosted their price target on Insulet from $175.00 to $200.00 and gave the stock an "outperform" rating in a research report on Thursday. Twelve equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $185.38.

Insulet Trading Down 6.2%

Shares of PODD stock opened at $146.51 on Friday. The firm has a market capitalization of $10.16 billion, a P/E ratio of 23.86, a P/E/G ratio of 1.21 and a beta of 1.06. Insulet has a twelve month low of $126.40 and a twelve month high of $354.88. The stock's fifty day simple moving average is $141.97 and its 200 day simple moving average is $176.65. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.59 by $0.40. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. During the same period in the previous year, the company posted $1.24 EPS. The firm's revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, sell-side analysts predict that Insulet will post 6.75 EPS for the current fiscal year.

Institutional Trading of Insulet

Institutional investors have recently modified their holdings of the company. Elevation Wealth Partners LLC grew its position in Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 104 shares during the period. Activest Wealth Management grew its holdings in shares of Insulet by 186.3% during the third quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 149 shares in the last quarter. WPG Advisers LLC lifted its holdings in Insulet by 169.3% in the third quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier's stock worth $35,000 after buying an additional 171 shares during the period. Covestor Ltd grew its holdings in Insulet by 103.9% during the third quarter. Covestor Ltd now owns 310 shares of the medical instruments supplier's stock valued at $40,000 after purchasing an additional 158 shares during the period. Finally, Jacobi Capital Management LLC purchased a new stake in shares of Insulet in the third quarter valued at $40,000.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.